JP2011157399A5 - - Google Patents

Download PDF

Info

Publication number
JP2011157399A5
JP2011157399A5 JP2011112835A JP2011112835A JP2011157399A5 JP 2011157399 A5 JP2011157399 A5 JP 2011157399A5 JP 2011112835 A JP2011112835 A JP 2011112835A JP 2011112835 A JP2011112835 A JP 2011112835A JP 2011157399 A5 JP2011157399 A5 JP 2011157399A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
virus
myxoma virus
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011112835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011157399A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011157399A publication Critical patent/JP2011157399A/ja
Publication of JP2011157399A5 publication Critical patent/JP2011157399A5/ja
Withdrawn legal-status Critical Current

Links

JP2011112835A 2003-03-07 2011-05-19 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用 Withdrawn JP2011157399A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45252103P 2003-03-07 2003-03-07
US60/452,521 2003-03-07
US45539303P 2003-03-18 2003-03-18
US60/455,393 2003-03-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006504071A Division JP4800924B2 (ja) 2003-03-07 2004-03-08 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用

Publications (2)

Publication Number Publication Date
JP2011157399A JP2011157399A (ja) 2011-08-18
JP2011157399A5 true JP2011157399A5 (https=) 2011-10-06

Family

ID=32965588

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006504071A Expired - Fee Related JP4800924B2 (ja) 2003-03-07 2004-03-08 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用
JP2011112835A Withdrawn JP2011157399A (ja) 2003-03-07 2011-05-19 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006504071A Expired - Fee Related JP4800924B2 (ja) 2003-03-07 2004-03-08 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用

Country Status (11)

Country Link
US (2) US7582614B2 (https=)
EP (1) EP1601376B1 (https=)
JP (2) JP4800924B2 (https=)
KR (1) KR101116858B1 (https=)
AU (1) AU2004216928B2 (https=)
CA (1) CA2517147C (https=)
IL (1) IL170601A (https=)
MX (1) MXPA05009526A (https=)
NZ (1) NZ541951A (https=)
RU (1) RU2362584C2 (https=)
WO (1) WO2004078206A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05009526A (es) * 2003-03-07 2005-12-15 Robarts Res Inst Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
AU2006222500B2 (en) * 2005-03-07 2011-09-01 Robarts Research Institute Use of a combination of Myxoma virus and rapamycin for therapeutic treatment
WO2007143538A2 (en) * 2006-06-01 2007-12-13 Robarts Research Institute Pike-a enhances infection by myxoma virus
MX2008015265A (es) 2006-06-01 2008-12-12 Robarts Res Inst Mutates del virus de mixoma para tratamiento del cancer.
CN104039333B (zh) 2011-06-09 2018-11-16 佛罗里达大学研究基金会有限公司 移植物抗宿主疾病的治疗或预防方法
WO2018091151A1 (en) * 2016-11-17 2018-05-24 Vcn Biosciences Sl Use of viral vectors in the treatment of retinoblastoma
WO2019048689A1 (en) 2017-09-11 2019-03-14 Imba - Institut Für Molekulare Biotechnologie Gmbh TUMOR ORGANOID MODEL
KR20190109379A (ko) * 2018-03-16 2019-09-25 바이로큐어 주식회사 암 치료를 위한 레오바이러스 및 믹소마폭스 바이러스의 병용
RU2699754C1 (ru) * 2018-05-08 2019-09-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Флуоресцирующая клеточная линия глиомы и способ её получения
WO2019227022A1 (en) 2018-05-25 2019-11-28 Bioventures, Llc Myxoma virus compositions and methods of use
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020036341A1 (ko) * 2018-08-17 2020-02-20 바이로큐어 주식회사 암 치료를 위한 다람쥐폭스 바이러스 및 믹소마폭스 바이러스의 병용
WO2020051248A1 (en) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
WO2020106880A1 (en) 2018-11-20 2020-05-28 Bioventures, Llc Cells for the production of viruses and methods of using the same
US11591616B1 (en) 2019-04-22 2023-02-28 Colorado State University Research Foundation Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
DE69722608T2 (de) 1996-01-25 2004-04-29 The University Court Of The University Of Glasgow, Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
JP2001510053A (ja) 1997-07-18 2001-07-31 カイロン コーポレイション レンチウイルスベクター
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
JP2003530301A (ja) 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション ウイルスを用いた新生物の処置
AU6175000A (en) * 1999-07-12 2001-01-30 Viron Therapeutics, Inc. Novel myxoma genes for immune modulation
MXPA05009526A (es) * 2003-03-07 2005-12-15 Robarts Res Inst Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
WO2007143545A2 (en) 2006-06-01 2007-12-13 Robarts Research Institute Tnf signaling in myxoma virus treatments

Similar Documents

Publication Publication Date Title
JP2011157399A5 (https=)
Rodrigues et al. Pathogenesis of cholangiocarcinoma
Jiang et al. The mechanisms of HBV-induced hepatocellular carcinoma
RU2018105985A (ru) Новый подход к лечению рака с применением иммуномодуляции
KR20170084034A (ko) 암 치료용 의약 조성물 제조에서의 아젤니디핀의 용도
JP2008507530A5 (https=)
JP2020517715A5 (https=)
CA2517147A1 (en) Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
Yuan et al. The malignant transformation of viral hepatitis to hepatocellular carcinoma: mechanisms and interventions
Javid et al. The role of viruses in cancer development versus cancer therapy: an oncological perspective
JP2014506233A5 (https=)
Zhao et al. The role of tumor microenvironment reprogramming in primary liver cancer chemotherapy resistance
JP2014523398A5 (https=)
Zou et al. Toll-like receptors in hepatocellular carcinoma: potential novel targets for pharmacological intervention
Zhang et al. Role of miRNA-122 in cancer
JP2008531739A5 (https=)
Zhou et al. Circular RNA-regulated autophagy is involved in cancer progression
RU2007137008A (ru) Применение комбинации вируса миксомы и рапамицина для терапевтического лечения
Saha et al. Impact of anesthetics on oncogenic signaling network: a review on propofol and isoflurane
CN101991579A (zh) 熊果酸作为抗结肠肿瘤药物的应用
CN104069509A (zh) Sr-b1作为鼻咽癌生物标记物及治疗靶点的应用
JP2015044878A5 (https=)
JP2013100370A5 (https=)
Thakur et al. Different chemosensitization approaches for the effective management of HNSCC
Yang et al. Liquiritin represses proliferation, migration and invasion of colorectal cancer cells through inhibition of the miR-671/HOXB3 signaling pathway